Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN 2 versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN 2 versus V CILLIN K.
PENICILLIN-2 vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic